SciBase Holding (STO:SCIB) Second Quarter 2024 Results
Key Financial Results
- Revenue: kr6.64m (up 31% from 2Q 2023).
- Net loss: kr15.1m (loss widened by 33% from 2Q 2023).
- kr0.081 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
SciBase Holding Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 6.5%. Earnings per share (EPS) also missed analyst estimates by 100%.
Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 17% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with SciBase Holding (at least 2 which are a bit unpleasant), and understanding them should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:SCIB
SciBase Holding
A medical technology company, develops and sells point-of-care platforms that utilizes electrical impedance spectroscopy for the evaluation of skin disorders in Europe, the United States, North America, Asia, Oceania, and internationally.
Medium-low with excellent balance sheet.
